Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: Exploratory results from a phase II study

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Fennell, Dean A ^a   Myrand, Scott P ^b   Nguyen, Tuan S ^b   Ferry, David ^b,c   Kerr, Keith M ^d   Maxwell, Perry ^e   Moore, Stephen D ^f   Visseren Grul, Carla ^b   Das, Mayukh ^b   Nicolson, Marianne C ^d  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c NEW CROSS HOSPITAL   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f Almac Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; CISPLATIN; INTERLEUKIN 1 RECEPTOR TYPE II; MESSENGER RNA; PEMETREXED; SURFACTANT PROTEIN B; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; TRANSCRIPTOME;

ABO GLYCOSYLTRANSFERASE GENE; ADVANCED CANCER; AGED; AQUAPORIN 4 GENE; ARTICLE; CANCER SURVIVAL; CHROMOSOME 16 OPEN READING FRAME 89 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN 1 RECEPTOR TYPE II GENE; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 1 GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAPSIN A GENE; NCK INTERACTING KINASE GENE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURFACTANT PROTEIN B GENE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2 GENE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CLUSTER ANALYSIS; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; THYMIDYLATE SYNTHASE; TRANSCRIPTOME;

EID: 84907586529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107455     Document Type: Article

References (34)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J., et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
2. Paz-Ares LG, de Marinis F, Dediu M, Thomas M., Pujol JL, et al. (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31: 2895-2902.
3. Mendelsohn LG, Shih C, Chen V.J., Habeck LL, Gates SB, et al (1999) Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26: 42-47.
4. Sigmond J, Backus HH, Wouters D, Temmink O.H., Jansen G., et al. (2003) Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66: 431-438.
5. Giovannetti E, Mey V, Nannizzi S., Pasqualetti G, Marini L, et al (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68: 110-118.
6. Ceppi P, Volante M, Saviozzi S., Rapa I, Novello S, et al (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596.
7. Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, et al (2013) Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced non-squamous non-small cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thoracic Oncol 8: 930-939.
8. Sun JM, Han J, Ahn J.S., Park K., Ahn MJ (2011) Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6: 1392-1399.
9. Chen CY, Chang YL, Shih J.Y., Lin JW, Chen KY, et al (2011) Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 74: 132-138.
10. Christoph DC, Asuncion BR, Hassan B, Tran C., Maltzman JD, et al (2013) Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 8: 19-30.
11. Tanney A, Oliver GR, Farztdinov V, Kennedy R.D., Mulligan JM, et al (2008) Generation of a non-small cell lung cancer transcriptome microarray. BMC Med Genomics 1: 20.
12. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
13. Katz S, Irizarry RA, Lin X, Tripputi M., Porter MW (2006) A summarization approach for Affymetrix GeneChip data using a reference training set from a large, biologically diverse database. BMC Bioinformatics 7: 464.
14. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289-300.
15. Ward JH (1963) Hierarchical grouping to optimize an objective function. J Am Statist Assoc 58: 236-244.
16. Wilkerson MD, Yin X, Walter V., Zhao N, Cabanski CR, et al (2012) Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One 7: e36530.
17. Afink GB, Veenboer G, de Randamie J, Keijser R, Meischl C., et al (2010) Initial characterization of C16orf89, a novel thyroid-specific gene. Thyroid 20: 811-821.
18. Turner BM, Cagle PT, Sainz I.M., Fukuoka J., Shen SS, et al (2012) Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 136: 163-171.
19. Lee JG, Kim S, Shim HS (2012) Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung. Lung Cancer 77: 156-161.
20. Khoor A, Whitsett JA, Stahlman M.T., Halter SA (1997) Expression of surfactant protein B precursor and surfactant protein B mRNA in adenocarcinoma of the lung. Mod Pathol 10: 62-67.
21. Tang X, Kadara H, Behrens C., Liu DD, Xiao Y, et al (2011) Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17: 2434-2443.
22. Xie Y, Wen X, Jiang Z., Fu HQ, Han H, et al (2012) Aquaporin 1 and aquaporin 4 are involved in invasion of lung cancer cells. Clin Lab 58: 75-80.
23. Warth A, Muley T, Meister M., Herpel E, Pathil A, et al (2011) Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer 11: 161.
24. Fu CA, Shen M, Huang B.C., Lasaga J., Payan DG, et al (1999) TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J Biol Chem 274: 30729-30737.
25. Shitashige M, Satow R, Jigami T., Aoki K, Honda K, et al (2010) Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res 70: 5024-5033.
26. Ellis B, Kaercher L, Snavely C., Zhao Y, Zou C (2012) Lipopolysaccharide triggers nuclear import of Lpcat1 to regulate inducible gene expression in lung epithelia. World J Biol Chem 3: 159-166.
27. Re F, Sironi M, Muzio M., Matteucci C, Introna M, et al (1996) Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. J Exp Med 183: 1841-1850.
28. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732.
29. Moldvay J, Jackel M, Bogos K., Soltész I, Agócs L, et al. (2004) The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 10: 85-88.
30. Yang L, Lin M, Ruan W.J., Dong LL, Chen EG, et al (2012) Nkx2-1: a novel tumor biomarker of lung cancer. J Zhejiang Univ Sci B 13: 855-866.
31. Wilkerson MD, Schallheim JM, Hayes D.N., Roberts PJ, Bastien RR, et al (2013) Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. J Mol Diagn 15: 485-497.
32. Sun JM, Han J, Ahn J.S., Park K., Ahn MJ (2011) Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6: 1392-1399.
33. Olsson ML, Chester MA (2001) Polymorphism and recombination events at the ABO locus: a major challenge for genomic ABO blood grouping strategies. Transfus Med 11: 295-313.
34. Hayes DN, Monti S, Parmigiani G., Gilks CB, Naoki K, et al (2006) Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24: 5079-5090.